Panacea Biotec announced that it was awarded a contract from United Nations International Children’s Emergency Fund (UNICEF) to supply 115 million doses of its bivalent oral polio vaccine (bOPV) worth ₹127 crore.

“In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we are delighted to inform you that Panacea Biotec Limited (“the Company”) has received a Letter of Award from UNICEF for supply of 115 million doses of its bivalent oral polio vaccine (bOPV) worth $14.95 million (₹127 crore) in CY2025,” the company said in a statement.

The bivalent oral polio vaccine (bOPV) is a vaccine that protects against poliovirus types 1 and 3. Many countries use the bOPV in their routine immunisation schedules and to respond to outbreaks.

In its financial results, Panacea Biotec reported a loss of ₹15.8 crore. This was in contrast to the same period in the previous fiscal year when the company had declared a profit of ₹10.98 crore. Compared to the previous quarter, the revenue declined by 15.2%.

The company reported a decline in Selling, General & Administrative expenses by 2.42% quarter-over-quarter (q-o-q), but saw an increase of 4.25% year-over-year (Y-o-Y). This indicates some cost control measures on a short-term basis, but an overall increase in these expenses compared to last year.

Shares of Panacea Biotec ended 2.1% higher on Tuesday at ₹438.

Also Read : BPCL wins bid for 150 MW solar PV project, to spend ₹756.45 crore over two years